TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03641534

Intervention type: PROCEDURE
Intervention: Orthogonal polarization spectral imaging (OPS)
Description: Measurement of capillary flow in the rectal microcirculation

Intervention type: PROCEDURE
Intervention: Urine collection (Foley catheter)
Description: For urinalysis, biochemistry, urine microscopy, pH, and culture.

Intervention type: PROCEDURE
Intervention: Urine collection (Foley catheter)
Description: For urinalysis, biochemistry, urine microscopy, pH, and culture.

Intervention type: PROCEDURE
Intervention: Urine collection (Foley catheter)
Description: For urinalysis, biochemistry, urine microscopy, pH, and culture.

Intervention type: PROCEDURE
Intervention: Venous blood samplings
Description: for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)

Intervention type: PROCEDURE
Intervention: Venous blood samplings
Description: for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)

Intervention type: PROCEDURE
Intervention: Venous blood samplings
Description: for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)

Intervention type: PROCEDURE
Intervention: Electrocardiogram
Description: all patients will have an ECG performed on enrolment as a non-invasive investigation

Intervention type: PROCEDURE
Intervention: Electrocardiogram
Description: all patients will have an ECG performed on enrolment as a non-invasive investigation

Intervention type: PROCEDURE
Intervention: Electrocardiogram
Description: all patients will have an ECG performed on enrolment as a non-invasive investigation

Intervention type: PROCEDURE
Intervention: GlycoCheck
Description: GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.

Intervention type: PROCEDURE
Intervention: GlycoCheck
Description: GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.

Intervention type: PROCEDURE
Intervention: GlycoCheck
Description: GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
Study: NCT03393429

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DAVID assisted training
Description: DAVID device assisted training under supervision

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: training recommendation
Description: training recommendation to stay active
Study: NCT04586634

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peristeen cone catheter
Description: The active intervention is the Peristeen cone catheter device. The comparator in this investigation is current standard of care for patients with LARS which is conservative bowel management.
Study: NCT02913027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External Exam
Description: The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bimanual Exam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speculum Exam
Study: NCT00672841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preemptive Therapy with Anidulafungin
Description: Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empiric antifungal therapy based on physician discretion.
Description: Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
Study: NCT01420562

Intervention type: PROCEDURE
Intervention: blood sampling
Description: During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.

Intervention type: PROCEDURE
Intervention: blood sampling
Description: During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
Study: NCT04382144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Patient will receive a single injection of a local anesthetic into the common extensor origin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Patient will receive a single injection of a local anesthetic into the common extensor origin.
Study: NCT00801697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: 4 mg VRC-HIVDNA044-00-VP administered as 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: 4 mg VRC-HIVDNA044-00-VP administered as 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: 4 mg VRC-HIVDNA044-00-VP administered as 1 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DNA Vaccine placebo
Description: 1 mL VRC-PBSPLA043-00-VP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DNA Vaccine placebo
Description: 1 mL VRC-PBSPLA043-00-VP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DNA Vaccine placebo
Description: 1 mL VRC-PBSPLA043-00-VP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd35
Description: VRC-HIVADV027-00-VP 1 x 10\^10 PU administered as 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd35
Description: VRC-HIVADV027-00-VP 1 x 10\^10 PU administered as 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd35
Description: VRC-HIVADV027-00-VP 1 x 10\^10 PU administered as 1 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rAd35 placebo
Description: 1 mL VRC-PBSPLA043-00-0VP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rAd35 placebo
Description: 1 mL VRC-PBSPLA043-00-0VP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rAd35 placebo
Description: 1 mL VRC-PBSPLA043-00-0VP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: 4 mg VRC-HIVADV038-00-VP administered as 1 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5
Description: 4 mg VRC-HIVADV038-00-VP administered as 1 mL

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rAd5 placebo
Description: 1 mL VRC-DILUENT013-DIL-VP

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rAd5 placebo
Description: 1 mL VRC-DILUENT013-DIL-VP
Study: NCT03284645

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg
Description: Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg
Description: Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg
Description: Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
Study: NCT03882996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.
Study: NCT03386214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.
Study: NCT03284645

Intervention type: DRUG
Intervention: Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg
Description: Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.

Intervention type: DRUG
Intervention: Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg
Description: Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
Study: NCT03386214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.
Study: NCT03284645

Intervention type: DRUG
Intervention: Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg
Description: Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.

Intervention type: DRUG
Intervention: Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily
Description: Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.

Intervention type: DRUG
Intervention: Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily
Description: Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.

Intervention type: DRUG
Intervention: Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily
Description: Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
Study: NCT01055405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 20mg TID orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID orally
Study: NCT03042416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DOPA
Description: 18F-DOPA intravenous injection single dose
Study: NCT02460523

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative
Description: 1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: 2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
Study: NCT01044953

Intervention type: OTHER
Intervention: shortened winter break
Description: winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
Study: NCT02506127

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuronetics XPLOR system
Description: Transcranial magnetic stimulation system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuronetics XPLOR system
Description: Transcranial magnetic stimulation system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronetics XPLOR system
Description: Transcranial magnetic stimulation system
Study: NCT03572400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
Study: NCT03784859

Intervention type: DEVICE
Intervention: Insertion of Tissue Expander with Fluid Reservoir
Description: Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
Study: NCT03386214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: -Standard of care outside of protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: -Standard of care outside of protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: -Standard of care outside of protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: * Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
Study: NCT02228135

Intervention type: DRUG
Intervention: Dexamethasone

Intervention type: DRUG
Intervention: Dexamethasone
Study: NCT04584216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steam Eye Mask with acupoints stimulation
Description: A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Steam Eye Mask
Description: A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
Study: NCT00735462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% imiquimod cream
Description: 2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.75% imiquimod cream
Description: 3.75% imiquimod cream applied daily to wart areas for up to 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream applied daily to wart areas for up to 8 weeks
Study: NCT00700453

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group with no video game play
Description: Subjects will abstain from all video game play during study participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control 2
Description: Subjects will play 1 week of violent video game play followed by 1 week of no video game play.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VG1 group (2 weeks of violent video game play)
Description: Subjects will play a violent video game for 2 weeks of study participation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
Study: NCT01263990

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: NexFin
Description: noninvasive finger cuff system
Study: NCT00668512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antimelanoma injection of GSL alpha-Gal
Description: Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
Study: NCT04853407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005 extended-release tablet
Description: orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005 extended-release tablet
Description: orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once a day
Study: NCT02090998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPG Block with 5% Lidocaine gel
Description: cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPG Block with 5% Lidocaine gel
Description: cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
Study: NCT01742650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screw fixation
Description: 3,5mm fully threaded cortical screw transfixation of syndesmosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TightRope
Description: TightRope transfixation of syndesmosis
Study: NCT01856010

Intervention type: OTHER
Intervention: ECT treatment
Description: The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.

Intervention type: OTHER
Intervention: Standard Care (Non-ECT group)
Description: The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
Study: NCT04397146

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Supplement (ONS)
Description: Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
Study: NCT03857737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic submucosal dissection
Description: Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
Study: NCT01933659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSW
Description: ingesting DSW 200 cc four times a day (one hour before meal and bed time)
Study: NCT02625571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase-based treatment of sexual behavior problems of children
Study: NCT01585688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hLL1-DOX (IMMU-115)
Description: hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
Study: NCT04185142

Intervention type: COMBINATION_PRODUCT
Intervention: cryoballoon ablation combining with left atrial appendage closure
Description: cryoballoon ablation using either 1st or 2nd generation of cryoballoon and left atrial appendage closure using devices including WATCHMAN, Lefort and Lacbes.